Kim Helen Susan
Director at Applied Molecular Transport Inc.; EVP, Business Development at Kite Pharma, Inc.
- Sold, on record
- $29.4M
- Dollars the filings state
- Form 4 sales
- 13
- Latest Aug 27, 2021
- Form 144 notices
- 0
- Proposed sales
- Companies
- 2
- Filed as an executive or holder
Companies
- Applied Molecular Transport Inc.Director
- Kite Pharma, Inc.EVP, Business Development
Sales by reason
Form 4 sales per month, last 12 months.
Sales by company
- Applied Molecular Transport Inc.225,000 shares
- Kite Pharma, Inc.210,356 shares
Shares sold, every Form 4 sale on record.
Timeline
- 1 Form 4 sale Kite Pharma, Inc.Plan not statedJun 1, 2017 2017
Sold 2,400 shares at $72.45 ($174k)
Kim Helen Susan, EVP, Business Development
Sold 11.4% of holdings ($1.5M position)18,664 shares left1x usual sizeFiling
- 2 Form 4 sale Kite Pharma, Inc.UnusualJul 31, 2017 +60 days
Sold 26,649 shares at $109.28 ($2.9M)
Kim Helen Susan, EVP, Business Development
Sold 58.8% of holdings ($5M position)18,664 shares left11.1x usual sizeFiling
- 3 Form 4 sale Kite Pharma, Inc.UnusualAug 8, 2017 +8 days
Sold 79,949 shares at $119.56 ($9.6M)
Kim Helen Susan, EVP, Business Development
Sold 81.1% of holdings ($11.8M position)18,664 shares left33.3x usual sizeFiling
- 4 Form 4 sale Kite Pharma, Inc.UnusualAug 10, 2017 +2 days
Sold 6,251 shares at $120.09 ($751k)
Kim Helen Susan, EVP, Business Development
Sold 25.1% of holdings ($3M position)18,664 shares left0.4x usual sizeFiling
- 5 Form 4 sale Kite Pharma, Inc.Plan not statedSep 25, 2017 +46 days
Sold 3,171 shares at $179.66 ($570k)
Kim Helen Susan, EVP, Business Development
Sold 12.8% of holdings ($4.5M position)21,693 shares left0.5x usual sizeFiling
- 6 Form 4 sale Applied Molecular Transport Inc.UnusualJul 2, 2021 +1376 days
Sold 200,000 shares at $43.32 ($8.7M)
Kim Helen Susan, Director
Sold 25% of holdings ($34.7M position)600,000 shares leftFirst sale on recordFiling
- 7 Form 4 sale Applied Molecular Transport Inc.Plan not statedAug 25, 2021 +54 days
Sold 9,986 shares at $30.08 ($300k)
Kim Helen Susan, Director
Sold 1.7% of holdings ($18M position)590,014 shares leftFiling
- 8 Form 4 sale Applied Molecular Transport Inc.Plan not statedAug 27, 2021 +2 days
Sold 15,014 shares at $30.20 ($453k)
Kim Helen Susan, Director
Sold 2.5% of holdings ($17.8M position)575,000 shares leftFiling
Every transaction
Loading transactions…
Sales and notices (13)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Aug 27, 2021 | Aug 27, 2021 | Applied Molecular Transport Inc. | Director | Form 4 sale | 15,014 | $453k | 2.5% | Plan not stated | SEC |
| Aug 25, 2021 | Aug 25, 2021 | Applied Molecular Transport Inc. | Director | Form 4 sale | 9,986 | $300k | 1.7% | Plan not stated | SEC |
| Jul 2, 2021 | Jul 6, 2021 | Applied Molecular Transport Inc. | Director | Form 4 sale | 200,000 | $8.7M | 25.0% | Unusual | SEC |
| Sep 25, 2017 | Sep 27, 2017 | Kite Pharma, Inc. | EVP, Business Development | Form 4 sale | 3,171 | $570k | 12.8% | Plan not stated | SEC |
| Aug 10, 2017 | Aug 14, 2017 | Kite Pharma, Inc. | EVP, Business Development | Form 4 sale | 6,251 | $751k | 25.1% | Unusual | SEC |
| Aug 8, 2017 | Aug 10, 2017 | Kite Pharma, Inc. | EVP, Business Development | Form 4 sale | 79,949 | $9.6M | 81.1% | Unusual | SEC |
| Jul 31, 2017 | Aug 1, 2017 | Kite Pharma, Inc. | EVP, Business Development | Form 4 sale | 26,649 | $2.9M | 58.8% | Unusual | SEC |
| Jun 1, 2017 | Jun 5, 2017 | Kite Pharma, Inc. | EVP, Business Development | Form 4 sale | 2,400 | $174k | 11.4% | Plan not stated | SEC |
| May 1, 2017 | May 3, 2017 | Kite Pharma, Inc. | EVP, Business Development | Form 4 sale | 2,400 | $197k | 11.4% | Plan not stated | SEC |
| Apr 3, 2017 | Apr 4, 2017 | Kite Pharma, Inc. | EVP, Business Development | Form 4 sale | 2,400 | $196k | 11.4% | Plan not stated | SEC |
| Mar 1, 2017 | Mar 2, 2017 | Kite Pharma, Inc. | EVP, Business Development | Form 4 sale | 50,300 | $3.4M | 72.9% | Unusual | SEC |
| Dec 20, 2016 | Dec 22, 2016 | Kite Pharma, Inc. | EVP, Business Development | Form 4 sale | 936 | $48k | 10.4% | Plan not stated | SEC |
| Aug 15, 2016 | Aug 16, 2016 | Kite Pharma, Inc. | EVP, Business Development | Form 4 sale | 35,900 | $2.2M | 80.0% | Unusual | SEC |